Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Health Care Losses Limited As Investors Seek Less Trade-Sensitive Areas -- Health Care Roundup

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/03/2019 | 05:13pm EST

Health-care companies fell, but held up better than the broader market as investors sought out sectors less susceptible to changes in the odds of a U.S.-Chinese trade deal.

Japanese drug maker Astellas Pharma agreed to buy Audentes Therapeutics for about $3 billion in cash, in a deal Astellas said would provide it with a pipeline of gene therapies for rare diseases. Other developers of rare-disease drug treatments, such as Amicus Therapeutics, rose in sympathy.

Shares of biotech company Immunomedics fell sharply after-hours after it began selling a $250 million follow-on offering of shares.

Write to Rob Curran at rob.curran@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC.
12/10ASTELLAS PHARMA : Announces Key Leadership Promotions in Human Resources, Legal
AQ
12/04Nikkei bounces back on trade deal hopes, steelmakers shine
RE
12/03Japanese shares slip on concerns of longer trade war
RE
12/03Health Care Losses Limited As Investors Seek Less Trade-Sensitive Areas -- He..
DJ
12/03Wall Street falls as trade hopes wane
RE
12/03ASTELLAS PHARMA : Presents New Data on XOSPATA in FLT3 Mutation-Positive Relapse..
AQ
12/03Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merc..
AQ
12/03Japan's Astellas to buy Audentes for $3 billion in high-priced gene therapy b..
RE
12/03Nikkei slips on fresh global trade concerns, weak U.S. data
RE
12/02NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials (JPY)
Sales 2020 1 263 B
EBIT 2020 258 B
Net income 2020 200 B
Finance 2020 429 B
Yield 2020 2,18%
P/E ratio 2020 17,5x
P/E ratio 2021 16,9x
EV / Sales2020 2,45x
EV / Sales2021 2,35x
Capitalization 3 523 B
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 2 070,00  JPY
Last Close Price 1 881,00  JPY
Spread / Highest target 43,5%
Spread / Average Target 10,0%
Spread / Lowest Target -33,5%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Senior Executive Officer & Head-Finance
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC.36.21%32 404
JOHNSON & JOHNSON8.87%368 436
ROCHE HOLDING AG25.45%262 617
MERCK AND COMPANY16.11%226 847
PFIZER-11.84%212 953
NOVARTIS22.87%209 790